Xiaoyuan Dong1, Wen Wang1, Hui Qu2, Dong Han3, Junmin Zheng4, Guorui Sun2. 1. a Department of Hematology and. 2. b Department of Gastrointestinal Surgery , Qilu Hospital of Shandong University , Ji'nan , Shandong , P.R. China . 3. c Department of General Surgery , People's Hospital of Laiwu City Laicheng District , Laiwu , Shandong , P.R. China , and. 4. d Department of General Surgery , People's Hospital of Weifang City Fangzi District , Weifang , Shandong , P.R. China.
Abstract
PURPOSE: Lymph cancers are heterogeneous malignancies of the hematopoietic and lymphoid tissues. Doxorubicin (DOX) and vincristine (VCR) are commonly used anti-cancer chemotherapeutic drugs, but their clinical uses are associated with dose-limiting systemic toxicity. METHODS: In the present study, DOX and VCR were encapsulated into nanostructured lipid carriers (NLCs) and used them to treat B-cell lymphoma cells through the targeted delivery of DOX and VCR to lymph cancer animal model. RESULTS: DOX and VCR encapsulated NLCs (DOX/VCR NLCs) demonstrated controlled drug release under physiological conditions. In addition, DOX/VCR NLCs exhibited the highest cytotoxicity and synergistic effect of two drugs in B-cell lymphoma cells and the best anti-tumor effect in vivo. CONCLUSION: DOX/VCR NLCs were proved to be more efficacious than the equivalent dose of free DOX and single drug (DOX or VCR) formulation in vitro and in vivo, and significantly reduced the drug-associated systemic toxicity.
PURPOSE:Lymph cancers are heterogeneous malignancies of the hematopoietic and lymphoid tissues. Doxorubicin (DOX) and vincristine (VCR) are commonly used anti-cancer chemotherapeutic drugs, but their clinical uses are associated with dose-limiting systemic toxicity. METHODS: In the present study, DOX and VCR were encapsulated into nanostructured lipid carriers (NLCs) and used them to treat B-cell lymphoma cells through the targeted delivery of DOX and VCR to lymph cancer animal model. RESULTS:DOX and VCR encapsulated NLCs (DOX/VCR NLCs) demonstrated controlled drug release under physiological conditions. In addition, DOX/VCR NLCs exhibited the highest cytotoxicity and synergistic effect of two drugs in B-cell lymphoma cells and the best anti-tumor effect in vivo. CONCLUSION:DOX/VCR NLCs were proved to be more efficacious than the equivalent dose of free DOX and single drug (DOX or VCR) formulation in vitro and in vivo, and significantly reduced the drug-associated systemic toxicity.
Authors: DanDan Zhang; Yan Yan Kong; Jia Hui Sun; Shao Jie Huo; Min Zhou; Yi Ling Gui; Xu Mu; Huan Chen; Shu Qin Yu; Qian Xu Journal: Int J Nanomedicine Date: 2017-03-16
Authors: Gustavo Henrique Rodrigues da Silva; Ludmilla David de Moura; Fabíola Vieira de Carvalho; Gabriela Geronimo; Talita Cesarim Mendonça; Fernando Freitas de Lima; Eneida de Paula Journal: Molecules Date: 2021-11-17 Impact factor: 4.411